CPRX Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of 34.1% compared to Catalyst Pharmaceuticals's net margin of 25.86%. Catalyst Pharmaceuticals's return on equity of 27.81% beat Corcept Therapeutics's return on equity of 25.77%.

Catalyst Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 49.17%. On the other hand Corcept Therapeutics has an analysts' consensus of -- which suggests that it could grow by 43.57%. Given that Catalyst Pharmaceuticals has higher upside potential than Corcept Therapeutics, analysts believe Catalyst Pharmaceuticals is more attractive than Corcept Therapeutics.

Catalyst Pharmaceuticals has a beta of 0.748, which suggesting that the stock is 25.213% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.513, suggesting its less volatile than the S&P 500 by 48.73%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $128.7M, which are smaller than Corcept Therapeutics quarterly revenues of $182.5M. Catalyst Pharmaceuticals's net income of $43.9M is lower than Corcept Therapeutics's net income of $47.2M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 18.32x while Corcept Therapeutics's PE ratio is 41.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.72x versus 9.25x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regenxbio has a net margin of 34.1% compared to Catalyst Pharmaceuticals's net margin of -246.3%. Catalyst Pharmaceuticals's return on equity of 27.81% beat Regenxbio's return on equity of -69.62%.

Catalyst Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 49.17%. On the other hand Regenxbio has an analysts' consensus of $37.64 which suggests that it could grow by 408.6%. Given that Regenxbio has higher upside potential than Catalyst Pharmaceuticals, analysts believe Regenxbio is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.748, which suggesting that the stock is 25.213% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.243, suggesting its more volatile than the S&P 500 by 24.251%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $128.7M, which are larger than Regenxbio quarterly revenues of $24.2M. Catalyst Pharmaceuticals's net income of $43.9M is higher than Regenxbio's net income of -$59.6M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 18.32x while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.72x versus 4.19x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 34.1% compared to Catalyst Pharmaceuticals's net margin of 7.2%. Catalyst Pharmaceuticals's return on equity of 27.81% beat Sarepta Therapeutics's return on equity of 12.48%.

Catalyst Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 49.17%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.10 which suggests that it could grow by 51.85%. Given that Sarepta Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.748, which suggesting that the stock is 25.213% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $128.7M, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. Catalyst Pharmaceuticals's net income of $43.9M is higher than Sarepta Therapeutics's net income of $33.6M. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 18.32x while Sarepta Therapeutics's PE ratio is 79.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.72x versus 7.48x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 34.1% compared to Catalyst Pharmaceuticals's net margin of 37.71%. Catalyst Pharmaceuticals's return on equity of 27.81% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Catalyst Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 49.17%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 20.93%. Given that Catalyst Pharmaceuticals has higher upside potential than Vertex Pharmaceuticals, analysts believe Catalyst Pharmaceuticals is more attractive than Vertex Pharmaceuticals.

Catalyst Pharmaceuticals has a beta of 0.748, which suggesting that the stock is 25.213% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

Catalyst Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catalyst Pharmaceuticals pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Catalyst Pharmaceuticals quarterly revenues are $128.7M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Catalyst Pharmaceuticals's net income of $43.9M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Catalyst Pharmaceuticals's price-to-earnings ratio is 18.32x while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catalyst Pharmaceuticals is 5.72x versus 10.00x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.